Tadao Akizawa
Showa University
Internal medicineUrologyEndocrinologySurgeryIntensive care medicineProspective cohort studyAdverse effectCohort studyHyperparathyroidismHemodialysisAnemiaErythropoietinKidney diseaseSecondary hyperparathyroidismDialysisParathyroid hormoneNephrologyMedicineGastroenterology
540Publications
62H-index
12.3kCitations
Publications 545
Newest
#1Satoshi Onozawa (Astellas Pharma)
#2Tomomi Kimura (Astellas Pharma)H-Index: 10
Last. Tadao Akizawa (Showa University)H-Index: 62
view all 4 authors...
Anemia status may be transient. Causal associations between changes in anemia status over time and adverse outcome development are not well characterized in community-dwelling subjects at the beginning of impaired kidney function. This retrospective cohort study used annual health checkup and medical and pharmacy claims data from the JMDC between January 2005 and June 2019. Community-dwelling subjects in Japan with a pre-index estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2 follo...
Source
#1Hiroyasu Yamamoto (Jikei University School of Medicine)H-Index: 20
#2Kiyoshi Nobori (Bayer)
Last. Tadao Akizawa (Showa University)H-Index: 62
view all 6 authors...
INTRODUCTION Erythropoiesis-stimulating agents (ESAs) are the current standard of care for anemia due to chronic kidney disease (CKD) in patients not undergoing dialysis. Molidustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is being investigated as an alternative treatment for renal anemia. Molidustat was evaluated in five phase 3 studies, the molidustat once daily improves renal anemia by inducing erythropoietin (MIYABI) program. The present study investigated the safety a...
2 CitationsSource
#1Hiroyasu Yamamoto (Jikei University School of Medicine)H-Index: 20
#2Kiyoshi Nobori (Bayer)
Last. Tadao Akizawa (Showa University)H-Index: 62
view all 6 authors...
INTRODUCTION Molidustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that predominantly induces renal production of erythropoietin (EPO). Molidustat was evaluated for the treatment of anemia associated with chronic kidney disease (CKD) in the "Molidustat Once Daily Improves Renal Anemia by Inducing EPO" (MIYABI) program, which comprises 5 phase 3 clinical trials. The present MIYABI Non-Dialysis Correction (ND-C) study investigated the efficacy and safety of molidustat in Japa...
Source
#1Fumihiko Koiwa (Showa University)H-Index: 19
#2Shin TokunagaH-Index: 4
Last. Tadao Akizawa (Showa University)H-Index: 62
view all 6 authors...
Introduction null Evocalcet is a recently approved calcimimetic agent for secondary hyperparathyroidism (SHPT). In this study, the efficacy and safety of once-daily oral evocalcet were evaluated in patients without prior cinacalcet use (nonusers) and previously treated patients (users). null null null Methods null This post hoc analysis of a previous phase III head-to-head comparison study included SHPT patients treated with evocalcet with or without prior cinacalcet use. Endpoints included tren...
Source
#1Tadao Akizawa (Showa University)H-Index: 62
#2Masaomi Nangaku (UTokyo: University of Tokyo)H-Index: 80
Last. Hideki HirakataH-Index: 57
view all 7 authors...
Enarodustat (JTZ-951) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor developed for treating anemia in chronic kidney disease. Two open-label, uncontrolled phase 3 studies evaluated the 52-week safety and efficacy of enarodustat in Japanese anemic patients with chronic kidney disease not on dialysis (n = 132) [SYMPHONY ND-Long study] or on maintenance hemodialysis (n = 136) [SYMPHONY HD-Long study]. The most frequent adverse events were viral upper respiratory tract infection (2...
1 CitationsSource
#1Tadao Akizawa (Showa University)H-Index: 62
#2Kiyoshi Nobori (Bayer)
Last. Hiroyasu Yamamoto (Jikei University School of Medicine)H-Index: 20
view all 7 authors...
This 36-week, open-label, single-arm, phase 3 study investigated the safety and efficacy of molidustat in Japanese patients with renal anemia undergoing peritoneal dialysis. Molidustat was titrated every 4 weeks to maintain Hb levels within the target range (≥11.0 and <13.0 g/dL). The primary efficacy outcome was the responder rate, defined as the proportion of patients who met all of the following criteria: (1) mean Hb levels in the target range during the evaluation period (Weeks 30-36); (2) ≥...
1 CitationsSource
#1Tadao Akizawa (Showa University)H-Index: 62
#2Takashi Yamada (Bayer)H-Index: 2
Last. Hiroyasu Yamamoto (Jikei University School of Medicine)H-Index: 20
view all 7 authors...
Introduction null Molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor for renal anemia treatment, was evaluated in 5 phase 3 studies (MIYABI program). We report the results of the MIYABI hemodialysis-maintenance study. null null null Methods null This 52-week, randomized, double-blinded, double-dummy study compared the efficacy and safety of molidustat and darbepoetin in Japanese patients receiving hemodialysis and erythropoiesis-stimulating agents. Molidustat (starting dose: 75 ...
1 CitationsSource
#1Tadao Akizawa (Showa University)H-Index: 62
Last. Masafumi Fukagawa (Tokai University)H-Index: 69
view all 5 authors...
Introduction null The current management of hyperphosphatemia with phosphate binders is associated with insufficient phosphorus control and a significant pill burden. Tenapanor, a first-in-class, phosphate absorption inhibitor, is expected to control phosphorus and decrease pill burden because of its small pill size and twice daily dosing regimen. This study evaluated tenapanor effectiveness on reducing the phosphate binder pill burden during a 26-week treatment period in Japanese hemodialysis p...
Source
#1Takashi HaraH-Index: 1
#2Miho KimachiH-Index: 8
Last. Yosuke YamamotoH-Index: 19
view all 5 authors...
1 CitationsSource
#1Takashi Shigematsu (Wakayama Medical University)H-Index: 40
Last. Tadao Akizawa (Showa University)H-Index: 62
view all 6 authors...
INTRODUCTION Phosphate binders are used to treat hyperphosphatemia. Some patients have inappropriately controlled serum phosphorus levels, which may occur for many reasons, including a high pill burden and adverse events (AEs). Tenapanor selectively inhibits the passive paracellular transfer of phosphate in the gastrointestinal tract, thereby reducing serum phosphorus levels. This novel mechanism of action may contribute to improved phosphate management. The efficacy and safety of tenapanor have...
Source